Reify Health, a leading provider of solutions that empower the clinical trial ecosystem, announced a $220M Series D round co-led by Altimeter Capital and Coatue, joined by Dragoneer Investment Group and existing investors ICONIQ Growth, Adams Street, and Battery Ventures.
This round of funding, which brings the company’s valuation to over $4.8 billion, was secured to accelerate the company’s efforts to improve diversity and representation in clinical trial participation.
Our global healthcare system relies on clinical trials to develop new, life-saving treatments for patients. Reify Health powers a more effective research ecosystem—one that is faster, more reliable, more cost efficient, and most importantly, more accessible to patients. Through its business entities, StudyTeam and Care Access, the company delivers best-in-class trial optimization technology and provides a pioneering decentralized clinical trial infrastructure that makes clinical research accessible for anyone, anywhere. With this new funding, Reify Health will aim these proven solutions at a challenge that has plagued the clinical trial industry for decades: improving diversity in clinical trial participation.
Certain minority communities have been heavily underrepresented in clinical trials, which presents a significant health equity issue. Treatments can work differently for different races and ethnicities. Those differences should be understood in the controlled setting of a clinical trial first, not in day-to-day healthcare after the medicine is made available to the public. Over the last several years, key stakeholders that include the FDA, biopharmaceutical companies, medical research institutions, and non-profit organizations have initiated efforts to increase diversity in clinical trial participation. However, meaningful progress has been slow to come.
Ralph Passarella, CEO of Reify Health, said:
As we looked at what needs to be done to bring representation and inclusion to clinical trials, we reached two conclusion. First, while we all want a quick solution, this is a complex, multi-layered problem that will require significant resource commitments over the next decade to achieve meaningful, long-lasting improvements. Second, we recognized that we are uniquely positioned to do work that can make an impact on this problem through our two businesses, Care Access and StudyTeam. We see what needs to be done and have a way to contribute, so we have the responsibility to act.
To contribute to this effort, Reify Health is launching BRIDGE (Bringing Representation, Inclusion, and Diversity to Global Enrollment), an initiative aimed at devoting the company’s capabilities in partnership with like-minded organizations to achieve two primary objectives:
- Build a robust understanding, both qualitative and quantitative, of the barriers to underrepresented minority groups participating in clinical trials.
- Deliver solutions that overcome these barriers, so clinical trials are more representative of the patient populations they aim to treat.
Through BRIDGE, Reify and its partners will make commitments to achieve specific goals over the next ten years.
Michael Lin, Executive Chair of Reify Healthv, said:
Our announcement today about capital investment and long-term commitment speaks to the size of the challenge ahead to make clinical trials more representative. When we celebrated the ten-year anniversary of our company in March of 2022, the message to our team and partners was: ‘The last ten years have been about building a foundation, and the next ten years are about making an impact at scale.’ BRIDGE represents the magnitude of impact we aim to make in life sciences in our next decade.
Ahmad Namvargolian, CEO of Care Access, said:
We are building the next generation of clinical trial infrastructure—the roads and highways of where clinical trials can go and who they reach. As we lay this foundation, we have the opportunity to fill historical gaps and have a responsibility to make diversity, inclusion, and representation a foundational element in clinical trials moving forward.
Reify Health has already begun work in this direction through StudyTeam and Care Access. For example, the StudyTeam enrollment management platform recently added its Diversity Reporting capability so research sponsors can measure and understand the gaps in their enrollment strategy and take immediate action to help increase representation where needed. Care Access continues to expand on its capabilities to bring a clinical trial almost anywhere so more communities, including traditionally underrepresented communities, have the option to participate.